Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ozanimod versus interferon beta-1a in relapsing multiple sclerosis
2014-002320-27Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in multiple sclerosis (MS) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Annual relapse rate during the treatment period. Started Oct 2014; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-002320-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002320-27.